MONTEREY PARK, CA – June 6, 2005 – GeneFluidics, Inc., a point of care clinical diagnostic company, announced today that its Chief Executive, Dr. Vincent Gau, will present the Company’s
technological and corporate development progress at the National Cancer Institute’s conference entitled “Moving Biosensors to Point-of-Care Cancer Diagnostics.” This conference will present novel technologies as well as foster dialogue amongst cancer diagnostic researchers and biosensor engineers. Dr. Gau will give two presentations, including “The Clinical Application of Nanotechnology-Enabled Molecular Analysis” and “Bionanotechnology Meets Microfluidics for ‘Plug and Play’ Diagnostics.” More information on the conference can be found at https://cms.palladianpartners.com/cms/1111782287/.
GeneFluidics is commercializing a novel molecular analysis platform that integrates bionanotechnology and microfluidics. The platform has two distinct yet synergistic components –
electrochemical detection, embodied in a multichannel reader and plastic sensor chips, and automated sample preparation, embodied in microfluidic cartridges and associated reader
fluidic controls. By integrating these components, the platform enables the rapid detection and quantification of genetic material, proteins, and small molecules in raw samples without the use of target amplification methods such as PCR.
Vincent Gau – CEO
845 Meridian Street
Irwindale, CA 91010
NOTE: Contact information on this page was updated from the original press release, which used the previous address for GeneFluidics.